-
Medigene AG Reports Full-Year 2023 Financial Results and Provides Corporate Update
28 Mar 2024 06:30 GMT
… March 28, 2024. Medigene AG (Medigene or the “Company”, FSE … Chief Executive Officer of Medigene. “Importantly, we advanced … promising commercial opportunities for Medigene.” Financial Guidance 2024 … press release --- About Medigene AG
Medigene AG (FSE: MDG1 …
-
Medigene AG to participate in the H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference
19 Mar 2024 13:00 GMT
… Martinsried, March 19, 2024. Medigene AG (Medigene or the “Company”, FSE: … press release --- About Medigene AG
Medigene AG (FSE: MDG1) … therapeutics pipeline and partnering. Medigene’s lead TCR-T … https://medigene.com/ Medigene AG Pamela Keck
…
-
Medigene AG to report full year 2023 financial results on March 28, 2024
18 Mar 2024 14:00 GMT
… & Media section on Medigene’s website: https:/… press release --- About Medigene AG
Medigene AG (FSE: MDG1) … therapeutics pipeline and partnering. Medigene’s lead TCR-T program … https://medigene.com/ Medigene AG
Pamela Keck
Phone …
-
Medigene to Present Favorable Safety Profile of TCR-T Cells upon Addition of Costimulatory Switch Protein with a Poster Presentation at AACR 2024 Annual Meeting
06 Mar 2024 10:00 GMT
… , March 6, 2024. Medigene AG (Medigene or the “Company”, FSE … press release --- About Medigene AG Medigene AG (FSE: MDG1) … actual results achieved by Medigene may differ significantly from … these forward-looking statements. Medigene® is a registered trademark …
-
Medigene AG expands patent portfolio in Japan for iM-TCR Technology
04 Mar 2024 13:57 GMT
… T cell (TCR-T) therapies
Medigene AG, an immuno-oncology platform … Patent Office protecting its inducible Medigene T cell receptor (iM-TCR … ,” said Selwyn Ho, CEO at Medigene.
The iM-TCR is a …
-
Medigene AG Expands Patent Portfolio in Japan for iM-TCR Technology to Directly Control TCR-T Safety and Efficacy, In Vivo
04 Mar 2024 07:00 GMT
… , March 4, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard … press release --- About Medigene AG Medigene AG (FSE: MDG1) … actual results achieved by Medigene may differ significantly from … these forward-looking statements. Medigene® is a registered …
-
Medigene Presents at CAR-TCR Summit Europe Showcasing Unique Approach for Development of Differentiated TCR-T Therapies
29 Feb 2024 11:00 GMT
… , February 29, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard … Chief Scientific Officer of Medigene gave a presentation titled … press release --- About Medigene AG Medigene AG (FSE: MDG1) … E-mail: investor@medigene.com investor@medigene.com In case …
-
Medigene to Present at Upcoming Conferences
19 Feb 2024 13:00 GMT
… , February 19, 2024. Medigene AG (Medigene or the “Company”, FSE … press release --- About Medigene AG Medigene AG (FSE: MDG1) … therapeutics pipeline and partnering. Medigene’s lead TCR-T … https://medigene.com/. Medigene Pamela Keck
Phone: …
-
Medigene selects clinical indications for TCR-T therapy
13 Feb 2024 18:41 GMT
-
Medigene Announces Indication Selection for the Clinical Development of its Lead 3rd Generation TCR-T Therapy Program in Solid Tumors
12 Feb 2024 13:00 GMT
… , February 12, 2024. Medigene AG (Medigene, FSE: MDG1, Prime Standard … Chief Executive Officer at Medigene. “While clinical data for … press release --- About Medigene AG Medigene AG (FSE: MDG1) … these forward-looking statements. Medigene® is a registered …